Comirnaty Evropská unie - čeština - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použití této vakcíny musí být v souladu s oficiálními doporučeními.

Spikevax (previously COVID-19 Vaccine Moderna) Evropská unie - čeština - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

MATRIFEN 100MCG/H Transdermální náplast Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

matrifen 100mcg/h transdermální náplast

takeda pharma a/s, vallensbaek strand array - 2220 fentanyl - transdermální náplast - 100mcg/h - fentanyl

MATRIFEN 12MCG/H Transdermální náplast Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

matrifen 12mcg/h transdermální náplast

takeda pharma a/s, vallensbaek strand array - 2220 fentanyl - transdermální náplast - 12mcg/h - fentanyl

MATRIFEN 25MCG/H Transdermální náplast Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

matrifen 25mcg/h transdermální náplast

takeda pharma a/s, vallensbaek strand array - 2220 fentanyl - transdermální náplast - 25mcg/h - fentanyl

MATRIFEN 50MCG/H Transdermální náplast Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

matrifen 50mcg/h transdermální náplast

takeda pharma a/s, vallensbaek strand array - 2220 fentanyl - transdermální náplast - 50mcg/h - fentanyl

MATRIFEN 75MCG/H Transdermální náplast Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

matrifen 75mcg/h transdermální náplast

takeda pharma a/s, vallensbaek strand array - 2220 fentanyl - transdermální náplast - 75mcg/h - fentanyl

Artesunate Amivas Evropská unie - čeština - EMA (European Medicines Agency)

artesunate amivas

amivas ireland ltd - artesunate - malárie - antiprotozoály - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. pozornost by měla být věnována oficiálním doporučením pro správné používání činidel proti malárii.

ProMeris Evropská unie - čeština - EMA (European Medicines Agency)

promeris

pfizer limited  - metaflumizon - ektoparazitikum pro lokální použití, vč. insekticidy - kočky - léčba a prevence napadení blechami (ctenocephalides canis a c. felis) u koček. veterinární léčivý přípravek lze použít jako součást léčebné strategie pro alergickou dermatitidu blech (fad).

ProMeris Duo Evropská unie - čeština - EMA (European Medicines Agency)

promeris duo

pfizer limited  - metaflumizone, amitraz - ektoparazitikum pro lokální použití, vč. insekticidy - psi - pro léčbu a prevenci zamoření blechami (ctenocephalides canis a c. felis) a klíšťatům (ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus, dermacentor reticulatus a dermacentor variabilis), a léčba demodikózy (způsobené demodex spp. ) a vši (trichodectes canis) u psů. veterinární léčivý přípravek lze použít jako součást léčebné strategie pro alergickou dermatitidu blech (fad).